



COPY OF PERS
ORIGINAL FILED

1647 #8
Dmt
6-5-02

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: John E. Sims and Dirk E. Smith

Docket No.: 0317-US

Serial No.: 09/763,498

Group Art Unit: 1647

Filing Date: May 15, 2000

Examiner: F. Hamud

For: Human IL-1 Epsilon DNA and Polypeptides

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED

MAY 31 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Communication is responsive to the Office Action mailed January 24, 2002, in which the Examiner restricts the invention into groups I through IX and requires election of one of the inventions set forth by the Examiner. Applicants respectfully traverse the requirement to elect on the grounds that the claims as filed meet the unity of invention requirements. Applicants provisionally elect the invention of Group II.

The claims pending in this application are drawn to IL-1 Epsilon nucleic acids, vectors containing the nucleic acids, host cells containing the vectors, polypeptides, methods for producing the polypeptides and antibodies that bind the polypeptides. The nucleic acids of SEQ ID NO:5 are contained fully within the nucleic acids of SEQ ID NO:7 and SEQ ID NO:12. Furthermore, the nucleic acid of SEQ ID NO:7 and the nucleic acid of SEQ ID NO:12 differ by a single nucleic acid. That is, SEQ ID NO:12 is an IL-1 Epsilon polymorphism. The polypeptides are similarly related. In order to visualize the similarity, Applicants provide herewith a PILEUP of the sequences.

The Examiner insists that SEQ ID NO:7, SEQ ID NO:5 and SEQ ID NO:12 do not share a common technical feature which is based on a common property not found in the prior art. However, the Examiner provides no evidence to support this conclusion. Furthermore, the Examiner asserts that the encoded polypeptides and the nucleic acids are different, independent and distinct chemical compounds that lack either a common structural property which distinguishes them as a group from structurally related compounds of the prior art or which provides them with a common utility which is lacking from those prior art polypeptide or nucleic acids. Again, the Examiner provides only

conclusionary statements and provides no evidence to support the conclusion that unity of invention is not met.

With respect to the Examiner's requirement to elect one of the polypeptides (restrictions that involve Groups IV, V), the polypeptides of SEQ ID NO:7 and SEQ ID NO:13 have common structures and properties, which alone is sufficient to meet the unity of invention requirements. Applicants respectfully request that the Examiner withdraw the requirement as it relates to restricting the claimed polypeptides. In the absence of withdrawing the requirement, Applicants request that the Examiner demonstrate the basis for the lack of unity of invention.

As for the requirement to restrict the respective nucleic acid molecules, vectors, host cells and methods for preparing the polypeptides (Groups I, II, III, VI; VII), as described above, the nucleic acid molecules of SEQ ID NO:7 and 12 are structurally similar. SEQ ID NO:7 and SEQ ID NO:12 differ by one nucleotide. There is no basis for the Examiner to assert that the claim nucleic acid molecules are structurally different. Because the nucleic acids share significant structural elements, there is no basis for restricting the nucleic acids claims. Moreover, the Federal Circuit and the PTO have long recognized that claims to nucleic acids, vectors containing the nucleic acids, host cells containing the vectors and methods of using the host cells to produce a polypeptide are not separate inventions. To this end, the PTO examines these claims as one Group. Thus, the Examiner's view that claims of Groups V and VI should be restricted from each other, as well as restricted from Groups I, II and III is improper and without merit.

Finally, Applicants respectfully assert that it is improper, under unity of invention Rule 13, for the Examiner to require restriction between claims to polypeptides and claims to the nucleic acids that encode the polypeptides. The Examiner's attention is directed to Annex B Unity of Invention (PCT/AI/1 Rev.1) Example 17. This Example describes unity as present between Protein X (claim 1) and the DNA encoding protein X (Claim 1). In view of this clear mandate, Applicants request that the Examiner withdraw the requirement to restrict as between claims to polypeptide and claims to nucleic acids encoding the polypeptide.


In view of the foregoing, Applicants respectfully assert that claims to the polypeptides, claims to the nucleic acids that encode the polypeptides, claims to vectors, claims to host cells containing the vectors, and claims to processes for preparing the polypeptides meet the unity of invention requirements and are properly examined in a

Response to Restriction Requirement
Docket No. 0317-US

single application. Accordingly, Applicants request that the Examiner withdraw the restriction requirement as it relates to the claims of Groups I, II, III, IV, V, VI, and VII. In so doing, claims 21-39 will be properly the subject of examination in this application.

In view of the provisional election and traverse, Applicant requests favorable consideration of the restriction requirement and speedy allowance of the claims.

Respectfully submitted,


Janis C. Henry
Registration No. 34,347

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: May 14, 2002

Signed: 
Nanci M. Kertson



RECEIVED

MAY 31 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: John E. Sims and Dirk E. Smith

Docket No.: 0317-US

Serial No.: 09/763,498

Group Art Unit: 1647

Filing Date: May 15, 2000

Examiner: F. Hamud

For: Human IL-1 epsilon DNA and Polypeptides

COPY OF PAPERS
ORIGINALLY FILED

RESPONSE TO RESTRICTION REQUIREMENT

Appendix A: Multiple Alignment of the amino acid sequences of SEQ ID NOs:6, 8 and 13

!!AA_MULTIPLE_ALIGNMENT 1.0
PileUp of: @/tmp/GCGRMIServer/198.178.220.29-
1019766414427.pileup/pileup.list

Symbol comparison table: GenRunData:blosum62.cmp CompCheck: 1102

GapWeight: 8
GapLengthWeight: 2

stdout MSF: 158 Type: P April 25, 2002 13:26 Check: 399 ..

Name: SEQ ID NO:6 (SEQ 6) Len: 158 Check: 2077 Weight: 1.00
Name: SEQ ID NO:8 (SEQ 8) Len: 158 Check: 9155 Weight: 1.00
Name: SEQ ID NO:13 (SEQ 13) Len: 158 Check: 9167 Weight: 1.00

//

v. 1 50
SEQ 6 ~~~~~
SEQ 8 MEKALKIDTP QQGSIQDINH RVWVLQDQTL IAVPRKDRMS PVTIALISCR
SEQ 13, MEKALKIDTP QRGSIQDINH RVWVLQDQTL IAVPRKDRMS PVTIALISCR

51 100
SEQ 6 ~~~~~EK DIMDLYNQPE
SEQ 8 HVETLEKDRG NPIYLGLNGL NLCLMCAKVG DQPTLQLK
SEQ 13 HVETLEKDRG NPIYLGLNGL NLCLMCAKVG DQPTLQLK
** *****

101 150
SEQ 6 PVKSFLFYHS QSGRNSTFES VAFPGWFIAV SSEGGC~~~~~
SEQ 8 ~~~~~PLIL TQELGKANTT
SEQ 13 ~~~~~PLIL TQELGKANTT

151
SEQ 6 ~~~~~
SEQ 8 DFGLTMLF
SEQ 13 DFGLTMLF

* indicates identity between the three polypeptides compared



RECEIVED

MAY 3 1 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In the Application of: John E. Sims and Dirk E. Smith

Docket No.: 0317-US

Serial No.: 09/763,498

Group Art Unit: 1647

Filing Date: May 15, 2000

Examiner: F. Hamud

For: Human IL-1 epsilon DNA and Polypeptides

COPY OF PAPERS
ORIGINALLY FILED

RESPONSE TO RESTRICTION REQUIREMENT

Appendix B: Multiple Alignment of the amino acid sequences of SEQ ID NOs:5, 7 and 12

!!NA_MULTIPLE_ALIGNMENT 1.0
PileUp of: @/tmp/GCGRMIServer/198.178.220.29-
1019765667622.pileup/pileup.list

Symbol comparison table: GenRunData:pileupdna.cmp CompCheck: 6876

GapWeight: 5
GapLengthWeight: 1

stdout MSF: 477 Type: N April 25, 2002 13:14 Check: 8750 ..

Name:	SEQ 5	(SEQ ID NO:5)	Len:	477	Check:	2386	Weight:	1.00
Name:	SEQ 7	(SEQ ID NO:7)	Len:	477	Check:	3077	Weight:	1.00
Name:	SEQ 12	(SEQ ID NO:12)	Len:	477	Check:	3287	Weight:	1.00

//

	1							50
SEQ 5	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
SEQ 7	ATGGAAAAAG	CATTGAAAAT	TGACACACCT	CAGCAGGGGA	GCATTCAGGA			
SEQ 12	ATGGAAAAAG	CATTGAAAAT	TGACACACCT	CAGCGGGGA	GCATTCAGGA			

	51							100
SEQ 5	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
SEQ 7	TATCAATCAT	CGGGTGTGGG	TTCTTCAGGA	CCAGACGCTC	ATAGCAGTCC			
SEQ 12	TATCAATCAT	CGGGTGTGGG	TTCTTCAGGA	CCAGACGCTC	ATAGCAGTCC			

	101							150
SEQ 5	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
SEQ 7	CGAGGAAGGA	CCGTATGTCT	CCAGTCACTA	TTGCCTTAAT	CTCATGCCGA			
SEQ 12	CGAGGAAGGA	CCGTATGTCT	CCAGTCACTA	TTGCCTTAAT	CTCATGCCGA			

	151							200
SEQ	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
SEQ 7	CATGTGGAGA	CCCTTGAGAA	AGACAGAGGG	AACCCCATCT	ACCTGGGCCT			
SEQ 12	CATGTGGAGA	CCCTTGAGAA	AGACAGAGGG	AACCCCATCT	ACCTGGGCCT			



COPY OF PAPER
ORIGINALLY FILED

RECEIVED

MAY 31 2002

250
TECH CENTER 1600/2900

201
SEQ 5 ~~~~~
SEQ 7 GAATGGACTC AATCTCTGCC TGATGTGTGC TAAAGTCGGG GACCAGCCCA
SEQ 12 GAATGGACTC AATCTCTGCC TGATGTGTGC TAAAGTCGGG GACCAGCCCA

251 300
SEQ 5 ~~~~~ ~~~~GAAAAG GATATAATGG ATTTGTACAA CCAACCCGAG
SEQ 7 CACTGCAGCT GAAG
SEQ 12 CACTGCAGCT GAAG

301 350
SEQ 5 CCTGTGAAGT CCTTTCTCTT CTACCACAGC CAGAGTGGCA GGAACTCCAC
SEQ 7
SEQ 12

351 400
SEQ 5 CTTGAGTCT GTGGCTTTCC CTGGCTGGTT CATCGCTGTC AGCTCTGAAG
SEQ 7
SEQ 12

401 450
SEQ 5 GAGGCTGTCC TCTCATCCTT ACCCAAGAAC TGGGGAAAGC CAACACTACT
SEQ 7
SEQ 12

451 477
SEQ 5 GACTTTGGGT TAACTATGCT GTTTTAA
SEQ 7
SEQ 12

* indicates identity between the three polynucleotides compared